Small Molecules

13 Mar 2018 Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
13 Mar 2018 Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)
12 Mar 2018 INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
12 Mar 2018 IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer
12 Mar 2018 XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment
12 Mar 2018 Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome
12 Mar 2018 Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
12 Mar 2018 Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883
12 Mar 2018 Aironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research Network
12 Mar 2018 Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation
10 Mar 2018 TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
10 Mar 2018 Aradigm Submits Marketing Authorisation Application (MAA) to EMA for EU Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
10 Mar 2018 MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
08 Mar 2018 GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma
08 Mar 2018 Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
07 Mar 2018 EIP Pharma Publishes Positive Alzheimer's Disease Clinical Study Data with Neflamapimod
07 Mar 2018 Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
07 Mar 2018 Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis
07 Mar 2018 Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
07 Mar 2018 Eisai and Purdue Pharma announce positive topline results from key clinical studies of lemborexant including first-ever phase 3 head-to-head superiority comparison versus zolpidem ER in patients with sleep disorder
07 Mar 2018 Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials
06 Mar 2018 Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China
06 Mar 2018 Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
06 Mar 2018 Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery
06 Mar 2018 G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing